Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NSC117079 is an inhibitor of PHLPP.
In vivo | Animals administered the Phlpp inhibitor NSC117079 seven weeks post-injury exhibited sustained normal activity levels, in contrast to the control group which demonstrated reduced mobility and activity three months following joint injury. Additionally, NSC117079 significantly enhances the production of cartilage extracellular matrix components, namely glycosaminoglycans and aggrecan, in over 90% of human articular cartilage explants from osteoarthritis patients, alongside promoting increased phosphorylation of Phlpp1 substrates (AKT2, ERK1/2, and PKC) in human articular chondrocytes. A solitary intraarticular injection of NSC117079 effectively mitigates mechanical allodynia and decelerates articular cartilage deterioration in joints with a compromised meniscus. |
分子量 | 473.48 |
分子式 | C20H15N3O7S2 |
CAS No. | 500363-63-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (105.60 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NSC117079 500363-63-3 Others NSC-117079 NSC 117079 Inhibitor inhibitor inhibit